GlassScriptPhysician profile
Trevor Merrell
NPI 1881270684
$2,474.55
in general payments reported to CMS, 2019-2025
24 companies · $2,052 in 2025
The $2,052 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $423 · 2025: $2,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,474.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $343.82 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $340.32 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $280.59 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $178.89 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Insulet Corporation | $178.57 | 2024-2025 | Omnipod |
| Pfizer INC. | $150.70 | 2025 | |
| Sanofi-Aventis U.S. LLC | $130.84 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $93.97 | 2024-2025 | Fanapt, Hetlioz |
| Glaxosmithkline, LLC. | $88.85 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $80.98 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $73.32 | 2025 | Veozah |
| Amgen INC. | $71.88 | 2024-2025 | Repatha, Evenity, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $64.03 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $61.40 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $59.40 | 2024-2025 | Spravato |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $52.14 | 2025 | Heplisav-B |
| Lilly USA, LLC | $49.06 | 2024-2025 | Mounjaro, Zepbound |
| Alkermes, INC. | $39.40 | 2025 | Lybalvi |
| Novartis Pharmaceuticals Corporation | $36.33 | 2025 | |
| Merck Sharp & Dohme LLC | $25.60 | 2024 | Gardasil 9, M-M-R II, Gardasil |
| Xeris Pharmaceuticals, INC. | $24.69 | 2024 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $18.52 | 2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $16.27 | 2025 | Zoryve |
| Dexcom, INC. | $14.98 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trevor Merrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.